Health&Life Co

Health&Life Co Days Payable Outstanding

The Days Payable Outstanding (DPO) of Health&Life Co (1781.TWO) as of Nov 6, 2026 is 161.19. In the previous year, Days Payable Outstanding (DPO) was 96.92 — a change of 66.31% (higher).

Days Payable Outstanding

161.19

YoY

66.31%

Last updated:

Days Payable Outstanding (DPO) of Health&Life Co is 2025 161.19 . Days Payable Outstanding (DPO) of Health&Life Co was 2024 96.92 . It decreases by 66.31% higher compared to the previous year.

The Health&Life Co Days Payable Outstanding history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Days Payable Outstanding
Date
Days Payable Outstanding
Jan 1, 2018
68.47 TWD
Jan 1, 2019
111.54 TWD
Jan 1, 2020
132.43 TWD
Jan 1, 2021
86.13 TWD
Jan 1, 2022
89.68 TWD
Jan 1, 2023
141.15 TWD
Jan 1, 2024
96.92 TWD
Jan 1, 2025
161.19 TWD
The Health&Life Co Days Payable Outstanding history
YEARDays Payable OutstandingYoY
161.19+66.31%
96.92-31.34%
141.15+57.40%
89.68+4.13%
86.13-34.96%
132.43+18.73%
111.54+62.91%
68.47-24.08%
90.18+8.16%
83.38+54.09%
54.11-34.44%
82.53—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Health&Life Co Stock analysis

What does Health&Life Co do? Health&Life Co Ltd generates revenue through the manufacturing and distribution of cardiovascular disease, in-vitro diagnostics, and respiratory care products. The company's primary products include electronic sphygmomanometers such as blood pressure monitors, nebulizers, and blood glucose monitoring systems, which measure and record systolic and diastolic blood pressure and glucose levels. These products are sold domestically in Taiwan and internationally to overseas markets. The firm targets healthcare providers, clinics, and consumers seeking home health monitoring solutions for chronic conditions like hypertension and diabetes. The company's product portfolio focuses on electronic sphygmomanometers, which are essential for daily health monitoring. By offering devices that measure blood pressure and glucose levels, Health&Life Co Ltd caters to patients managing cardiovascular and metabolic diseases. The domestic market in Taiwan serves as a key sales channel, while overseas markets provide additional growth opportunities for the firm's diagnostic and respiratory care products. Health&Life Co Ltd's business model relies on direct sales of medical devices to healthcare institutions and end-users. The firm's electronic sphygmomanometers, including blood pressure monitors and blood glucose systems, are distributed through both domestic and international channels. This approach ensures consistent revenue streams from the ongoing demand for home health monitoring equipment among patients with chronic conditions. Health&Life Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Health&Life Co stock

Days Payable Outstanding (DPO) of Health&Life Co is 161.19 in 2025.

Days Payable Outstanding (DPO) of Health&Life Co changed from 96.92 to 161.19, representing a 66.31% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Days Payable Outstanding (DPO) Health&Life Co since 2006 – with annual values, charts, and detailed analysis.

DPO measures the average number of days a company takes to pay its suppliers. Higher DPO can improve cash flow but may strain supplier relationships.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Days Payable Outstanding (DPO)'s Health&Life Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Days Payable Outstanding (DPO)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Days Payable Outstanding (DPO).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Health&Life Co

All Key Metrics — Health&Life Co